Vivesto AB (STO:VIVE)
Sweden
· Delayed Price · Currency is SEK 0.0800
-0.0028 (-3.38%)
Mar 9, 2026, 5:29 PM CET
Vivesto AB Company Description
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden.
Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma.
The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers.
In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.
The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022.
Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
Vivesto AB
| Country | Sweden |
| Founded | 1988 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Erik Kinnman |
Contact Details
Address: Gustav III:s Boulevard 46 Solna, 169 73 Sweden | |
| Phone | 46 18 50 54 40 |
| Website | vivesto.com |
Stock Details
| Ticker Symbol | VIVE |
| Exchange | Nasdaq Stockholm |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0000722365 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D. | Chief Executive Officer |
| Robert Maiorana | Head of Accounting and Acting Chief Financial Officer |
| Teresa Fernandez Zafra | Chief Scientific Officer and Head of Preclinical Development & Clinical Operations |
| Urban Ekelund | IR Manager |
| John T. Cosby | Head of Regulatory Affairs |
| Dzianis Babrou | Head of Product Development |
| Henrik Rönnberg | Chief Medical Officer of Animal Health |
| Maria Nilsson Hagberg | Head of Regulatory Affairs |
| Johanna Rostin | Chief Regulatory Officer |
| Kia Bengtsson | Head of Clinical Development |